Stockwatch: Alexion, United Therapeutics, Intercept And "Alternative Facts"
Executive Summary
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?
You may also be interested in...
Alexion Battles UK & France Over Kanuma Price
Alexion is blaming arbitrary pricing systems in Europe for its reimbursement woes with ultra-rare disease drug Kanuma, but one analyst told the Pink Sheet that more creativity is needed from pharma when it comes to pricing orphan therapies.
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
In this tale of two companies, it's the best of times and the best of times. J&J gets immediate value by acquiring Actelion's blockbuster PAH franchise and its late-stage pipeline, while its stake in an Actelion spinout offers longer-term potential.
Alexion’s Soliris Slips Up In Pivotal PROTECT Kidney Transplant Study
A difficult December for Alexion sees a pivotal study of its blockbuster Soliris failing to show any benefit in preventing delayed graft function in kidney transplant patients, an indication for which there are no approved treatments.